Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumor-necrosis factor alpha inhibition: Results from the British Society for Rheumatology Biologics Register
Fagerli KM et al. Rheumatology (Oxford) 2018: key241. doi: 10.1093/rheumatology/key241
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.